News › Industry News

Obagi Medical Announces FDA Approval of Obagi saypha ChIQ Injectable Hyaluronic Acid Gel

June 15, 2026

Obagi MedicalWaldencast plc announced that the U.S. Food and Drug Administration (FDA) has approved Obagi® saypha® ChIQ™ injectable hyaluronic acid gel. The approval adds to Waldencast’s injectable portfolio following the launch of Obagi® saypha® MagIQ™.

Obagi saypha ChIQ, developed by Croma-Pharma GmbH, utilizes proprietary MACRO Core Technology to create a stable 3D HA matrix delivered with high usable HA content at injection, consistent particle distribution, and predictable injection force and swelling profiles. It is indicated for use in cheek augmentation and correction of midface contour deficiencies in patients over the age of 21.

Obagi shared interim data from its Aesthetic Leadership with Obagi Hyaluronic Acid (ALOHA) Program, the largest real-world evaluation of a newly launched HA dermal filler to date. Reportedly, 94% of injectors believe Obagi saypha MagIQ complements their current filler options. The data also indicated that 42.6% of practices using the product have evaluated Obagi skincare, compared to industry data showing only 1 in 10 filler visits includes a professional skincare purchase.

Waldencast plc recently entered into an agreement to sell dermatological skincare business Obagi Medical to Bridgepoint.

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Allergan Aesthetics’ Skinvive by Juvéderm Receives FDA Approval for the Improvement of Neck Appearance
    • MedSafe Becomes Gold Vendor Affiliate with the American Med Spa Association
    • FDA Approves First New Sunscreen Ingredient in 20 Years
    • Allergan Aesthetics Releases ‘The Aesthetics Evolution: What Consumers Really Want’ Highlighting Consumer Motivations and Expectations in Aesthetics
    • Moxie Announces Treatment Plans